ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc Approval Call Transcript

Mar 13, 2023 / 12:30PM GMT
Release Date Price: $19.41 (-4.71%)
Operator

Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals DAYBUE FDA Approval Call. My name is Michelle, and I will be your coordinator for today. (Operator Instructions)

I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please go ahead.

Mark C. Johnson
ACADIA Pharmaceuticals Inc. - VP of IR

Thank you. Good morning, and thank you for joining us on today's call to discuss the FDA approval of DAYBUE, trofinetide Oral Solution.

Today's agenda will commence with an introduction from Steve Davis, our Chief Executive Officer, followed by a review of the DAYBUE label and clinical data by Kathie Bishop, our Chief Scientific Officer and Head of rare disease. Then Brent and Tian will discuss our commercialization strategy for DAYBUE. Mark Schneider, our Chief Financial Officer, will provide financial details on our license agreement with Neuren Pharmaceuticals before turning it back to Steve Davis for closing remarks and opening up the call for your questions.

Also on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot